证券代码：688271 证券简称：联影医疗 公告编号：2023-027 上海联影医疗科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 股东大会召开日期：2023年8月30日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 召开日期时间：2023 年 8 月 30 日 14 点 00 分 召开地点：上海市嘉定区城北路 2258 号一楼 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 8 月 30 日至 2023 年 8 月 30 日采用上海证券 交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的 交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网投票平台的 （一） 股东大会类型和届次 2023 年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投 ...

独立董事提名人声明 提名人上海联影医疗科技股份有限公司董事会，现提名盛雷鸣为 上海联影医疗科技股份有限公司第二届董事会独立董事候选人，并已 充分了解被提名人职业专长、教育背景、工作经历、兼任职务等情况。 被提名人已书面同意出任上海联影医疗科技股份有限公司第二届董 事会独立董事候选人（参见该独立董事候选人声明）。提名人认为， 被提名人具备独立董事任职资格，与上海联影医疗科技股份有限公司 之间不存在任何影响其独立性的关系，具体声明如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行 政法规、规章及其他规范性文件，具有五年以上法律、经济、财务、 管理或者其他履行独立董事职责所必需的工作经验，并已根据《上市 公司高级管理人员培训工作指引》及相关规定取得独立董事资格证书。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要 求： （五）中国保监会《保险公司独立董事管理暂行办法》的规定； （六）其他法律、行政法规和部门规章规定的情形。 三、被提名人具备独立性，不属于下列情形： （一）在上市公司或者其附属企业任职的人员及其直系亲属、主 要社会关系（直系亲属是指配偶、父母、子女等；主要社会关系是指 兄弟姐妹 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2023-026 上海联影医疗科技股份有限公司 关于公司董事会、监事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）第一 届董事会、第一届监事会任期即将届满，为保证董事会、监事会的工作连续性， 公司根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板股票上市规则》等相关法律、法规及规范性文件和《上海联影医疗科技股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，开展了董事会、监事 会换届选举工作，现将本次董事会、监事会换届选举情况公告如下： 期三年。 公司独立董事对上述事项发表了同意的独立意见，具体内容详见公司于同日 在上海证券交易所网站（www.sse.com.cn）披露的《联影医疗独立董事关于公司 第一届董事会第二十次会议相关事项的独立意见》。 二、 监事会换届选举情况 公司于 2023 年 8 月 14 日召开了第一届监事会第十六次会议，审议通 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2023-019 为支持公司持续、稳定、健康发展，增强广大投资者信心，公司全体非独立 董事、监事、高级管理人员及核心技术人员张强先生、GUOSHENG TAN 先生、JUN BAO 先生、TAO CAI 先生、万莉娟女士、王洋先生、夏风华先生、QUN CHEN 先生、 HONGDI LI 先生、黄翔宇先生、俞晔珩女士、缪宏先生、吕云磊先生、汪淑梅女 士、YANFENG DU 先生、李国斌先生、向军先生、王超先生、安少辉先生、胡玮 先生承诺，自 2023 年 8 月 21 日起 6 个月内不转让或委托他人管理其所持在公司 首次公开发行前通过员工持股平台间接取得的份额（对应股份合计占联影医疗发 行后总股本的 3.07%），亦不会要求联影医疗回购其所持前述份额对应股份，因 联影医疗送红股、转增股本、配股等原因而增加的股份亦将遵守相关不减持的承 诺。 此外，公司实际控制人薛敏先生所持在公司首次公开发行前通过员工持股平 台间接取得的份额（占联影医疗发行后总股本的 1.20%），亦将严格遵守首次公 开发行时承诺，自公司股票在上海证券交易所科创板上市之日起 36 ...

关于上海联影医疗科技股份有限公司 中信证券股份有限公司、中国国际金融股份有限公司 首次公开发行部分限售股及战略配售限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）、中国国 际金融股份有限公司（以下简称"中金公司"、"保荐机构"）为上海联影医疗 科技股份有限公司（以下简称"公司"、"联影医疗"）首次公开发行股票并上 市的保荐机构。根据《中华人民共和国公司法》《中华人民共和国证券法》《证券 发行上市保荐业务管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等相关法律、法规和 规范性文件的规定，对联影医疗首次公开发行部分限售股及战略配售限售股上市 流通事项进行了核查，核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 6 月 22 日出具的《关于同意上海联 影医疗科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1327 号），公司获准向社会公开发行人民币普通股（A 股）100,000,000 股，并于 2022 年 8 月 22 日在上海证券交易所科创板上市交易。 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2023-020 上海联影医疗科技股份有限公司 首次公开发行部分限售股及战略配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海联影医疗科技股份有限公司（以下简称"联影医疗"或"公司"）本 次上市流通的战略配售限售股股份数量为 46,000,000 股，限售期为 12 个月。本 公司确认，上市流通数量为该限售期的全部战略配售股份数量。中信证券联影医 疗员工参与科创板战略配售 1 号集合资产管理计划、中信证券联影医疗员工参与 科创板战略配售 2 号集合资产管理计划、中信证券联影医疗员工参与科创板战略 配售 3 号集合资产管理计划、中信证券联影医疗员工参与科创板战略配售 4 号集 合资产管理计划（以下简称"员工资管计划"）参与公司首次公开发行战略配售， 合计获配 9,848,191 股股份（占联影医疗发行后总股本的 1.20%），根据合同约定， 员工资管计划自公司首次公开发行的股票上市起 18 个月内封闭运作，将遵守约 定不进行 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥2,212,870,463.39, representing a year-on-year increase of 33.42%[4] - Net profit attributable to shareholders was ¥329,659,181.62, reflecting a growth of 7.68% compared to the same period last year[4] - Operating profit for Q1 2023 was RMB 363,206,481.37, slightly up from RMB 360,574,427.16 in Q1 2022[17] - Net profit for Q1 2023 was RMB 325,526,611.76, compared to RMB 301,681,648.10 in Q1 2022, reflecting an increase of 7.9%[17] - Comprehensive income for Q1 2023 totaled RMB 320,718,943.78, compared to RMB 296,414,888.38 in Q1 2022, an increase of 8.2%[18] Research and Development - R&D investment totaled ¥430,404,096.92, which is 19.45% of the revenue, an increase of 4.05 percentage points year-on-year[4] - Research and development expenses for Q1 2023 amounted to RMB 412,457,903.29, up from RMB 225,313,935.37 in Q1 2022, indicating a significant investment in innovation[17] Cash Flow and Management - The net cash flow from operating activities was negative at -¥313,565,330.56, indicating a significant change in cash management[4] - Cash flow from operating activities in Q1 2023 was RMB 2,400,333,807.83, compared to RMB 1,358,475,956.46 in Q1 2022, showing a strong increase of 76.7%[19] - The company reported a net increase in cash and cash equivalents of -1,799,155,142.95, compared to -1,939,336,075.03 in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥24,233,214,669.96, showing a slight increase of 0.12% from the end of the previous year[5] - The company's current assets totaled RMB 20,167,991,458.87, compared to RMB 20,144,563,385.67 in the previous period, indicating a marginal increase of about 0.12%[13] - The total liabilities decreased to RMB 6,425,306,357.89 from RMB 6,731,009,468.77, representing a reduction of approximately 4.54%[15] - The company's equity attributable to shareholders increased to RMB 17,817,607,290.73 from RMB 17,483,275,310.26, reflecting a growth of approximately 1.91%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,877[8] - The top shareholder, 联影医疗技术集团, holds 20.33% of the shares, amounting to 167,550,968 shares[9] Government Subsidies - The company received government subsidies amounting to ¥41,348,453.47, which are closely related to its normal business operations[6] Operating Costs - Total operating costs for Q1 2023 were RMB 1,949,098,408.01, up from RMB 1,387,605,701.78 in Q1 2022, representing an increase of 40.5%[16] Tax and Other Income - The company’s tax expenses for Q1 2023 were RMB 34,014,094.44, down from RMB 53,418,742.19 in Q1 2022, reflecting a decrease of 36.4%[17] - Other income for Q1 2023 was RMB 108,082,436.09, compared to RMB 129,075,139.81 in Q1 2022, indicating a decrease of 16.3%[17]

Market Position and Growth - The company achieved a market share ranking of first in the domestic market for CT, PET/CT, PET/MR, and XR products, with over 1,000 top-tier hospitals in China adopting its full range of products [4]. - In 2022, the company reported a year-on-year revenue growth of 106.71% in international markets, driven by its innovative and high-quality products [6]. - The company has successfully entered over 50 countries and regions, including the United States, Japan, and Italy, expanding its global footprint and recognition [4]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in 2022, representing a growth of 15% year-over-year [17]. - The company’s overseas revenue reached 1.078 billion yuan, accounting for 11.94% of total revenue, with a year-on-year growth of 110.83% [121]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025 [18]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development efforts [28]. Research and Development - The company emphasizes the importance of independent research and development, aiming to master all core technologies and align with international standards [3]. - Research and development investments increased by 30%, focusing on innovative healthcare solutions [18]. - The company achieved a total R&D investment of approximately ¥1.47 billion, representing a 39.89% increase compared to the previous year [98]. - The number of R&D personnel has increased to 3,088, representing 42.29% of the total workforce, up from 39.19% in the previous year [109]. - The company has applied for a total of 8,677 intellectual property rights, with 4,357 granted, including 946 new invention patent applications during the reporting period [98][99]. - The company is committed to achieving a higher self-research ratio in its product lines, ensuring core technologies are independently controllable [172]. Financial Performance - The company's operating revenue for 2022 was CNY 9,238,122,700.80, representing a 27.36% increase compared to CNY 7,253,755,673.40 in 2021 [29]. - The net profit attributable to shareholders for 2022 was CNY 1,656,084,034.72, which is a 16.86% increase from CNY 1,417,184,821.29 in 2021 [29]. - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management [17]. - The company reported a significant increase in credit impairment losses, which rose by 390.06% to ¥94,489,727.17, attributed to higher bad debt provisions [129]. - The company reported a net profit margin of 12%, which is an improvement from 10% in the previous year [186]. Product Innovation - The company has launched innovative products such as the Total-body PET/CT uEXPLORER and the 5.0T MRI uMR Jupiter, which have redefined industry standards [3]. - The company has launched over 90 products with internationally leading performance indicators, including 10 products registered with NMPA and 39 products certified by the EU CE [38]. - The company has developed the industry's first 75cm large-bore 3.0T and 5.0T whole-body MRI products, as well as the first domestically produced 3.0T MR and 9.4T animal MR products [78]. - The company launched the uEXPLORER, the world's first 4D total-body PET/CT, which completes full-body high-definition scans in just 30 seconds using 1/40 of the typical dose [60]. - The company is focused on building a complete product ecosystem in the high-end medical equipment sector through integrated, intelligent, and diversified solutions [172]. Strategic Acquisitions and Partnerships - A strategic acquisition of a competitor was completed, valued at 300 million, aimed at enhancing technological capabilities [18]. - The company is exploring partnerships with leading tech firms to integrate AI into its product offerings, which is expected to drive future growth [18]. - The company is exploring partnerships with healthcare providers to enhance service delivery and improve patient outcomes [20]. - A strategic acquisition of a smaller tech firm was announced, valued at 300 million, aimed at enhancing the company's technological capabilities [186]. Governance and Compliance - There are no special arrangements for corporate governance or significant matters reported [11]. - The company confirms no non-operational fund occupation by controlling shareholders or related parties [11]. - The company assures that all directors can guarantee the authenticity, accuracy, and completeness of the annual report [12]. - The company has engaged PwC as its accounting firm, ensuring compliance and accuracy in financial reporting [27]. Market Trends and Challenges - The company acknowledges the challenges and opportunities presented by the ongoing transformation of the healthcare system in China [4]. - The global medical device market size exceeded $480 billion in 2021 and is projected to reach $848 billion by 2030, with a CAGR of 6.4% from 2021 to 2030 [72]. - The Chinese medical device market grew from ¥312.55 billion in 2015 to ¥778.93 billion in 2020, representing a CAGR of approximately 20.0% [75]. - The company is exposed to significant competition from established players like GE Healthcare, Siemens Healthineers, and Philips Healthcare, which dominate the high-end medical imaging market [125]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion [18]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies [21]. - The company plans to enhance its digital platform, aiming for a 40% increase in user engagement by the end of next year [18]. - The company plans to continue its governance practices in accordance with relevant laws and regulations [183].

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,686,550,783.48, representing a year-over-year increase of 6.66%[2] - The net profit attributable to shareholders for the same period was ¥124,972,562.07, with a year-over-year increase of 1.35%[2] - Net profit for Q3 2022 was ¥879,417,134.80, compared to ¥757,299,542.49 in Q3 2021, reflecting a 16.1% increase[18] - Earnings per share for Q3 2022 were ¥1.22, up from ¥1.06 in Q3 2021[19] - The company reported a total profit of ¥1,012,709,040.25 for Q3 2022, up from ¥928,998,947.93 in Q3 2021[18] Research and Development - Research and development expenses totaled ¥422,240,475.69 in Q3 2022, marking a significant increase of 45.71% compared to the previous year[4] - The ratio of R&D expenses to operating revenue was 25.04%, an increase of 6.71 percentage points year-over-year[4] - Research and development expenses for the first three quarters of 2022 totaled ¥867,972,581.95, an increase from ¥734,116,099.21 in 2021, indicating a focus on innovation[17] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥22,176,347,625.49, reflecting a substantial increase of 114.02% from the end of the previous year[4] - The company's total liabilities were RMB 5.50 billion, slightly up from RMB 5.33 billion, indicating a growth of about 3.2%[15] - The company's total liabilities and shareholders' equity increased to ¥22,176,347,625.49, compared to ¥10,361,883,193.35 in the previous year[16] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥864,422,041.45, indicating a significant cash outflow[4] - The cash inflow from operating activities for Q3 2022 was CNY 5,819,203,236.19, an increase from CNY 4,984,704,378.58 in Q3 2021, representing a growth of approximately 16.7%[20] - The net cash outflow from investment activities was CNY -1,596,647,075.84, compared to CNY -739,429,635.74 in the same period last year, indicating a decline in investment cash flow[21] - The cash inflow from financing activities was CNY 10,797,240,000.00, significantly higher than CNY 65,882,733.36 in Q3 2021, showing a substantial increase in financing[21] Equity and Shareholder Information - Shareholders' equity attributable to the parent company was ¥16,703,373,359.03, up 231.59% compared to the previous year[4] - The company's equity increased significantly, with paid-in capital rising to RMB 824.16 million from RMB 724.16 million, reflecting a growth of approximately 13.8%[15] Other Financial Metrics - The basic earnings per share for Q3 2022 was ¥0.16, a decrease of 2.95% year-over-year[4] - The diluted earnings per share for the same period was also ¥0.16, with a similar decrease of 2.95% year-over-year[4] - Other comprehensive income after tax for Q3 2022 was ¥12,844,348.90, compared to a loss of ¥7,086,245.76 in Q3 2021[19] - The company experienced a decrease in tax expenses, which were ¥133,291,905.45 in Q3 2022, down from ¥171,699,405.44 in Q3 2021[18] Inventory and Receivables - Accounts receivable rose to RMB 1.83 billion, compared to RMB 1.05 billion in the same period last year, representing a growth of approximately 74.4%[14] - Inventory levels increased to RMB 3.28 billion, up from RMB 2.21 billion, marking a rise of around 48.5%[14] Government Support - The company reported government subsidies recognized in the current period amounting to ¥104,410,819.32, contributing positively to the financial results[5] Market Activity - The company has not reported any significant new product launches or technological advancements during this quarter[12] - There are no indications of market expansion or mergers and acquisitions activities reported in this quarter[12]